MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL.
Işıl Altıntaş, Christopher Morehouse, Elena Favaro et al.
✦ AI-curated · Sources linked
In 30 seconds
The EPCORE NHL-1 trial evaluated the efficacy of epcoritamab, a CD3 × CD20 bispecific antibody, in patients with relapsed/refractory follicular lymphoma (FL) after at least two prior therapies. This Phase I/II multicenter study found that most patients achieved minimal residual disease (MRD) negativity by cycle 3 day 1, which correlated with prolonged progression-free survival (PFS), indicating the potential of MRD analysis in assessing treatment response.
Key findings
- Most MRD-evaluable patients reached MRD negativity by cycle 3 day 1.
- MRD negativity at cycle 3 day 1 correlated with prolonged progression-free survival.
- Patients with MRD positivity had shorter PFS compared to MRD negative patients at cycle 3 and cycle 5.
- MRD-negative responders had significantly improved PFS when adjusted for baseline clinical risk factors.
Why it matters
Understanding the correlation between MRD negativity and clinical outcomes can enhance treatment monitoring and decision-making in relapsed/refractory follicular lymphoma, potentially leading to better patient management strategies.